MAGen NOFOs published

NHGRI, in collaboration with the Office of Data Science Strategy, announces two Notices of Funding Opportunity for the creation of a consortium of MAGen Sites and a Coordinating Center.

UG3/UH3 (Clinical Trial Not Allowed) for MAGen Development Sites:

UG3/UH3(Clinical Trial Not Allowed) for a Coordinating Center

The National Human Genome Research Institute has issued two Notices of Funding Opportunity (NOFO) to solicit applications to explore the feasibility of developing Machine Learning (ML) and Artificial Intelligence (AI) tools that can enhance the accuracy and precision of predicting how individuals with pathogenic genetic variants manifest disease. NHGRI aims to establish a research Consortium, ML/AI Tools to Advance Genomic Translational Research (MAGen), to collaboratively identify both genomic and non-genomic factors influencing disease development in individuals carrying pathogenic genetic variants. The ML/AI tools will leverage existing multimodal genomic and non-genomic data and will be cross validated in genomic translational research settings to ensure the robustness and generalizability of the tools for translational purposes. In addition, the Consortium will explore the ethical, legal, and social implications (ELSI) of integrating ML/AI tools into genomic medicine through the establishment of an ELSI Framework for their development, and through implementation of ELSI research projects. The resources generated by the Consortium will be disseminated to the research community.